Sysmex Life Science

𝗝𝗼𝗶𝗻 𝗨𝘀 𝗮𝘁 𝗘𝗦𝗚𝗢 𝟮𝟬𝟮𝟱! We’re excited to be part of the 𝟮𝟲𝘁𝗵 𝗘𝗦𝗚𝗢 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀! 𝗩𝗶𝘀𝗶𝘁 𝗼𝘂𝗿 𝗦𝘆𝘀𝗺𝗲𝘅 𝗕𝗼𝗼𝘁𝗵 #𝗚𝟬𝟯 to explore the latest in 𝗴𝘆𝗻𝗮𝗲𝗰𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗰𝗮𝗻𝗰𝗲𝗿 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 and discover the 𝗢𝗦𝗡𝗔 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻 firsthand. 𝗪𝗵𝘆 𝗦𝘁𝗼𝗽 𝗯𝘆? ✅ Experience 𝗢𝗦𝗡𝗔 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 – faster results, improved workflow, and increased sensitivity. ✅ Connect with industry experts. ✅ Stay ahead in molecular diagnostics. ✅ Learn about the 𝗦𝗘𝗡𝗧-𝗢𝗦𝗡𝗔 𝗦𝘁𝘂𝗱𝘆. Learn more here: 👉 https://lnkd.in/eY39gjEU #ESGO2025 #SysmexEMEA

𝗘𝗦𝗚𝗢 𝟮𝟬𝟮𝟱 𝗶𝘀 𝗔𝗹𝗺𝗼𝘀𝘁 𝗛𝗲𝗿𝗲! 𝗗𝗼𝗻’𝘁 𝗠𝗶𝘀𝘀 𝗢𝘂𝘁! The 𝟮𝟲𝘁𝗵 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝗼𝗻 𝗚𝘆𝗻𝗮𝗲𝗰𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 is just around the corner! Are you ready to explore the future of 𝗴𝘆𝗻𝗮𝗲𝗰𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗰𝗮𝗻𝗰𝗲𝗿 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀? 𝗩𝗶𝘀𝗶𝘁 𝘂𝘀 𝗮𝘁 𝗕𝗼𝗼𝘁𝗵 #𝗚𝟬𝟯 to discover the groundbreaking 𝗢𝗦𝗡𝗔 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻 – delivering 𝗳𝗮𝘀𝘁𝗲𝗿 𝗿𝗲𝘀𝘂𝗹𝘁𝘀, 𝗶𝗺𝗽𝗿𝗼𝘃𝗲𝗱 𝘄𝗼𝗿𝗸𝗳𝗹𝗼𝘄, 𝗮𝗻𝗱 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲𝗱 𝘀𝗲𝗻𝘀𝗶𝘁𝗶𝘃𝗶𝘁𝘆 in molecular diagnostics. Learn more here: 👉 https://lnkd.in/eY39gjEU #ESGO25 #Sysmex

Did you know that the human papillomavirus (HPV) is one of the most common viral infections and a leading cause of cervical cancer, along with cancers in the throat, anus, and genital areas? This common virus infects both men and women, yet it’s preventable through vaccination. HPV vaccination is safe, effective, and life-changing. Whether you're a parent ensuring your child's wellbeing or looking out for your own, take a step today to protect yourself and your loved ones. #cervicalcancer #hpv

Sensitivity Matters! At the #SimposioBiopsiaLiquida, Dr. Sandra Pérez Buira from FUNDACIÓN JIMENEZ DIAZ shared groundbreaking results on the predictive and clinical value of highly sensitive ctDNA-based NGS in metastatic luminal breast cancer patients, using the Plasma-SeqSensei Breast Cancer IVD kit. Key findings include: - ESR1 mutations were detected in 45% of patients.  - 68% of mutations had a mutant allele fraction (MAF) below 1%. Discover how Plasma-SeqSensei enables the detection of critical mutations in breast cancer. Learn more here 👉 https://lnkd.in/eh-JDQtj #liquidbiopsy #Sysmex

A breakthrough in precision oncology! 🎉 The AZ Delta team, led by Prof. Geert Martens, has made a significant breakthrough with their latest research. Their study, "Surveillance of Disease Progression in Metastatic Breast Cancer by Molecular Counting of Circulating Tumour DNA Using Plasma-SeqSensei™ Breast Cancer in Vitro Diagnostics Assay", showcases the power of personalised medicine. Key highlights: ✅Patient-centred approach: The Plasma-SeqSensei™ Breast Cancer kit enables tailored ctDNA thresholding for each patient. ✅Enhanced sensitivity: The kit is as sensitive as ddPCR and outperforms tissue NGS, providing a deeper understanding of mutation dynamics. ✅ Focus on ESR1: The research offers valuable insights into the role of ESR1 mutations in disease progression. This is a major step forward in improving patient outcomes and treatment strategies. Congratulations to the entire team on this remarkable achievement! Read the full paper here:  👉 https://lnkd.in/ewg3CHUj #Sysmex #LifeScience

Cost-effectiveness of liquid biopsy in colorectal cancer: Insights from Prof. Schramm Our latest article in LIQUID BIOPSY IMPACT discusses a recent health economics study with its author Prof. Wendelin Schramm, exploring the cost-effectiveness of NGS-based liquid biopsy for detecting CRC recurrence. This innovative technology holds immense promise for transforming patient care. Discover the latest insights and join the conversation!   Read more here:  https://lnkd.in/ervwYvWN #Sysmex #liquidbiopsy #colorectalcancer #cancercare 

𝗧𝗼𝗽 𝟯 𝗧𝗵𝗶𝗻𝗴𝘀 𝘁𝗼 𝗞𝗻𝗼𝘄 𝗔𝗯𝗼𝘂𝘁 𝘁𝗵𝗲 𝗦𝘂𝗿𝗲𝗦𝗲𝗾™ 𝗖𝗟𝗟 + 𝗖𝗡𝗩 𝗩𝟯 𝗣𝗮𝗻𝗲𝗹: 1. Enhanced gene coverage: The panel offers increased coverage for key genes like TP53, BTK, PLCG2, BCL2, and NRAS, aligning with the latest CLL research to provide a more comprehensive understanding of CLL progression. 2. High sensitivity and accuracy: The panel detects low-frequency SNVs and indels down to 1-2.5% VAF and CNVs down to 20% tumour estimation in the 5 most frequently aberrant regions, minimising the risk of missed variant calls. 3. Newly added internal reference DNA: This addition ensures accurate sample characterisation and increased lab efficiency by reducing inter-run variability. Check here for more details 👉 https://lnkd.in/e39WtpjN

💙 This #Movember, deepen your understanding of advancements in prostate cancer care. Tune in to an insightful webinar featuring Dr Cuadras and Dr Semidey, where they discuss how implementing OSNA supports patient management in prostate cancer. Gain valuable insights, and learn about the outcome of the multicentric POPCORN study, as well. Watch the webinar here: 👉 https://lnkd.in/e8P4QM58 #Sysmex

𝗟𝘂𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿: 𝗦𝗵𝗶𝗻𝗶𝗻𝗴 𝗮 𝗹𝗶𝗴𝗵𝘁 𝗼𝗻 𝗻𝗲𝘄 𝘀𝘁𝗮𝗴𝗶𝗻𝗴 𝘁𝗲𝗰𝗵𝗻𝗶𝗾𝘂𝗲𝘀! This Lung Cancer Awareness Month, we're excited about advancements in early detection! A new study by Romano et al. explores using sentinel lymph node mapping (SLN) to improve staging for stage I non-small cell lung cancer (NSCLC). What's the main takeaway? ✅ More precise staging: This technique helps doctors pinpoint the spread of cancer more accurately. ✅ Early detection of advanced stages: It can identify small metastases missed by traditional methods, potentially leading to earlier treatment for some patients who might be upstaged to stage IIIA. ✅ Reduced surgery risks: By identifying the key lymph nodes, it could reduce the need for extensive lymph node removal, minimising surgical complications. This innovative approach could revolutionise how we stage early-stage NSCLC, leading to better surgical outcomes. Want to learn more? Check out the full study here: https://lnkd.in/exaU7bbi #Sysmex #lungcancer

Exciting news for Breast Cancer Awareness Month! Dr Alessandra Virga and Prof sara bravaccini from the IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST Srl latest publication with Plasma-SeqSensei is out! The Novel AKT1, ERBB2, ESR1, KRAS, PIK3CA, and TP53 NGS Assay: A Non-Invasive Tool to Monitor Resistance Mechanisms to Hormonal Therapy and CDK4/6 Inhibitors is now available!  The study used Sysmex’s Plasma-SeqSensei Breast Cancer IVD to assess the biomarkers from 16 HR+/HER2-negative breast cancer patients. The team then monitored the patients at baseline (T0) and again 3 months (T1) into treatment. Here's a sneak peek of what they discovered: Takeaway: Alterations in PIK3CA are linked to poorer PFS, aligning with recent findings in the field. Plasma-SeqSensei detected mutations in key genes, including ESR1, down to a sensitivity of 0.06%. Conclusion: Plasma-SeqSensei is easy to use and highly accurate, detecting gene alterations as low as 0.06% MAF—an essential tool for precision oncology in HR+/HER2-negative breast cancer.  👉 https://lnkd.in/ezBgr-hi #Sysmex #BreastCancer